Advancements in GU Cancers: Key Data from AUA 2024
Jason Hafron, MD
Carissa Chu. MD
Optimal Sequencing of ADCs in Endocrine Refractory HR+/HER2- Metastatic Breast Cancer
Javier Cortes, MD, PhD
Komal Jhaveri, MD, FACP
GPRC5D-Targeted Bispecifics in Relapsed/Refractory Multiple Myeloma: Practical Expert Consensus on a New Target with Unique Adverse Events
Jeffrey V. Matous, MD
Donna Catamero, NP
Ajai Chari, MD
Applying SDM to Personalize Treatment Discussions on Recurrence Risk Reduction in Patients with Early-Stage Melanoma
Meghan Mooradian, MD
Emerging ADC Therapies for NSCLC: Anticipating AEs Reported in Clinical Trials
Egbert Smit, MD
Managing ADC-Related Pulmonary and Cardiac AEs in NSCLC
Mastering the AEs of ADCs to Unlock Their Full Potential in Breast, Lung, and Gynecologic Cancer
Nadia Harbeck, MD, PhD
Susana Campos, MD, MPH
ADC-Related Hematologic Adverse Events
Optimal Management of ADC-Related Gastrointestinal AEs in NSCLC
Hematologic Adverse Events With ADCs in Breast Cancer: Optimal Management Strategies
Risk Reduction and Management Protocols for Gastrointestinal Adverse Events With ADC Therapy in Breast Cancer
Managing Pulmonary and Cardiac Adverse Events Related to ADC Therapy in Breast Cancer
Gastrointestinal and Hematologic TEAEs Related to ADC Therapy in Gynecologic Cancers
ADCs in Gynecologic Cancers: Managing Pulmonary and Cardiac TEAEs
ADCs on the Horizon for Breast Cancer: Managing Treatment-Emergent Toxicities
Loading...
We’re glad to see you’re enjoying Prova Education… but how about a more personalized experience?
Press cancel to remain on Prova Education. Press the link below or the continue button to keep going.